|
1
|
Aggarwal P: Cervical cancer: Can it be
prevented? World J Clin Oncol. 5:775–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fojo A, Hamilton TC, Young RC and Ozols
RF: Multidrug resistance in ovarian cancer. Cancer. 60:(8 Suppl).
S2075–S2080. 1987. View Article : Google Scholar
|
|
3
|
Gong J, Jaiswal R, Mathys JM, Combes V,
Grau GE and Bebawy M: Microparticles and their emerging role in
cancer multidrug resistance. Cancer Treat Rev. 38:226–234. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lage H: Gene therapeutic approaches to
overcome ABCB1-Mediated drug resistance. Recent Results Cancer Res.
209:87–94. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Izquierdo MA, Shoemaker RH, Flens MJ,
Scheffer GL, Wu L, Prather TR and Scheper RJ: Overlapping
phenotypes of multidrug resistance among panels of human
cancer-cell lines. Int J Cancer. 65:230–237. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu L, Shen Y, Peng X, Zhang S, Wang M, Xu
G, Zheng X, Wang J and Lu C: Aberrant promoter methylation of
cancer-related genes in human breast cancer. Oncol Lett.
12:5145–5155. 2016.PubMed/NCBI
|
|
7
|
Karabulut S, Kaya Z, Amuran GG, Peker I,
Özmen T, Gūllūoḡlu BM, Kaya H, Erzik C, Ōzer A and Akkiprik M:
Correlation between the DNA methylation and gene expression of
IGFBP5 in breast cancer. Breast Dis. 36:123–131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dong X and Mumper RJ: Nanomedicinal
strategies to treat multidrug-resistant tumors: Current progress.
Nanomedicine (Lond). 5:597–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li WT, Aizimu A and Wang YH: Relationship
between the expression of P-glycoprotein and the therapeutic effect
of neoadjuvant chemotherapy on Uygur and Han patients with cervical
cancer. J Chin Pract Diagn Ther. 25:225–227. 2011.
|
|
10
|
Tydén E, Skarin M and Höglund J: Gene
expression of ABC transporters in Cooperia oncophora after field
and laboratory selection with macrocyclic lactones. Mol Biochem
Parasitol. 198:66–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Q, Wang J, He H, Liu H, Yan X and
Zou K: Trametenolic acid B reverses multidrug resistance in breast
cancer cells through regulating the expression level of
P-glycoprotein. Phytother Res. 28:1037–1044. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stewart DJ: Tumor and host factors that
may limit efficacy of chemotherapy in non-small cell and small cell
lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wood N and Streckfus CF: The expression of
lung resistance protein in saliva: A novel prognostic indicator
protein for carcinoma of the breast. Cancer Invest. 33:510–515.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu D, Shi HC, Wang ZX, Gu XW and Zeng YJ:
Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and
LRP as prognostic factors in primary ovarian carcinoma. Br J Biomed
Sci. 68:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li YJ, Yu CH, Zhang W and Liu Y and Liu Y:
The relationship between expression of COX-2′LRP and metastasis and
prognosis in patients with non-small cell lung carcinoma. J Clin
Pulm Med. 15:1707–1709. 2010.
|
|
16
|
Jiao JW and Wen F: Tanshinone IIA acts via
p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and
lung-resistance protein in cisplatin-resistant ovarian cancer
cells. Oncol Rep. 25:781–788. 2011.PubMed/NCBI
|
|
17
|
Zhong H, Zuo Y, Wu X, Peng Y, He H, Yang
J, Guan C and Xu Z: Synergistic antitumor effect of amorphigenin
combined with cisplatin in human lung adenocarcinoma A549/DDP
cells. Zhongguo Fei Ai Za Zhi. 19:805–812. 2016.(In Chinese).
PubMed/NCBI
|
|
18
|
Daukantienė L, Kazbarienė B, Valuckas KP,
Didžiapetrienė J, Krikštaponienė A and Aleknavičius E: The
significance of reduced glutathione and glutathione S-transferase
during chemoradiotherapy of locally advanced cervical cancer.
Medicina (Kaunas). 50:222–229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sato A, Shimada K, Nakamachi M, Ushio J,
Yamamoto W, Kurihara M and Matsukawa M: Effectiveness of
doxifluridine (5′-DFUR)/docetaxel against advanced/recurrent
gastric cancer showing resistance to various anticancer drug
regimens. Gastric Cancer. 5:233–236. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagai N1, Shiroyama Y, Oshita T, Mukai K,
Shigemasa K, Fujii T, Katsube Y, Matsubayashi S, Murakami T and
Ohama K: Tumor dihydropyrimidine dehydrogenase activity in advanced
cervical carcinoma. Oncol Rep. 9:1033–1040. 2002.PubMed/NCBI
|
|
21
|
Lou JY, Peng ZL, Zheng Y, Wang H, He B and
Wang HJ: Reversal of multi-drug resistance in ovarian cancer cell
by RNA interference. Zhonghua Fu Chan Ke Za Zhi. 41:413–416.
2006.PubMed/NCBI
|
|
22
|
Gao GL, Tu KJ and Liu FJ: Expression and
reversal of multi-drug resistance gene in ovarian cancer. Chin Clin
Oncol. 15:870–873. 2010.
|
